Department of Gynecology and Gynecological Oncology, Agaplesion Markus Hospital, Frankfurt am Main, Germany.
Department of Medical Oncology, The Christie Hospital, Manchester, UK.
Future Oncol. 2019 Apr;15(10):1147-1165. doi: 10.2217/fon-2018-0728. Epub 2019 Feb 22.
As originator biologic medicines lose patent protection, some biopharmaceutical companies are focusing on developing similar versions of these costly and complex therapies with a goal of providing more affordable treatment options. Many of these molecules, known as biosimilars, are now approved worldwide and several more are expected to be introduced in the near future. As more biosimilars become available, it is important for clinicians to become familiar with this new category of products and understand how biosimilars are developed, how their development differs from that of originator biologics and how they differ from generics. This review aims to provide the practicing clinician with the knowledge needed to understand biosimilars, along with some guidance on their use in treating oncologic diseases.
随着原创生物制药失去专利保护，一些生物制药公司正专注于开发这些昂贵且复杂疗法的类似版本，以期提供更实惠的治疗选择。许多此类分子被称为生物类似药，现已在全球获得批准，预计近期还将有更多产品问世。随着越来越多的生物类似药上市，临床医生了解这一新类别的产品变得尤为重要，需要了解生物类似药的开发方式、与原创生物制品的开发区别以及与仿制药的区别。本文旨在为临床医生提供理解生物类似药所需的知识，并就其在治疗肿瘤疾病中的应用提供一些指导。
